Melis Daniela, Pivonello Rosario, Parenti Giancarlo, Della Casa Roberto, Salerno Mariacarolina, Lombardi Gaetano, Sebastio Gianfranco, Colao Annamaria, Andria Generoso
Department of Pediatrics, Federico II University, Naples, Italy.
J Pediatr. 2007 Mar;150(3):300-5, 305.e1. doi: 10.1016/j.jpeds.2006.11.056.
To investigate the hypothalamus-pituitary-thyroid axis in patients with glycogen storage disease type 1(GSD1).
Ten patients with GSD1a, 7 patients with GSD1b, and 34 sex- and age-matched healthy control subjects were enrolled in the study.
The levels of serum-free thyroxine (FT4) were significantly lower in patients with GSD1a and GSD1b (P < .05), whereas thyrotropin was significantly higher compared with control subjects only in patients with GSD1b (P < .005). Thyroglobulin and thyroperoxidase auto-antibodies were significantly higher in patients with GSD1b than in patients with GSD1a and control subjects (P < .005). After thyrotropin-releasing hormone stimulation, an enhanced thyrotropin response was found in patients with GSD1a and patients with GSD1b (P < .005) compared with control subjects. The presence of a subclinical or overt hypothyroidism was found in 4 of 7 patients with GSD1b and in no patient with GSD1a (chi2 = 7.47, P < .005) or control subject (chi2 = 27.2, P < .0001).
Patients with GSD1b have an increased prevalence of thyroid autoimmunity and hypothyroidism, although patients with GSD1a have little evidence of thyroid abnormalities. Concomitant damage at the level of the hypothalamus or pituitary gland might be hypothesized on the basis of the slightly elevated thyrotropin levels, even in patients with overt hypothyroidism.
研究1型糖原贮积病(GSD1)患者的下丘脑 - 垂体 - 甲状腺轴。
本研究纳入了10例GSD1a患者、7例GSD1b患者以及34名性别和年龄匹配的健康对照者。
GSD1a和GSD1b患者的血清游离甲状腺素(FT4)水平显著降低(P < 0.05),而仅GSD1b患者的促甲状腺素水平与对照者相比显著升高(P < 0.005)。GSD1b患者的甲状腺球蛋白和甲状腺过氧化物酶自身抗体显著高于GSD1a患者和对照者(P < 0.005)。促甲状腺素释放激素刺激后,与对照者相比,GSD1a患者和GSD1b患者的促甲状腺素反应增强(P < 0.005)。7例GSD1b患者中有4例存在亚临床或显性甲状腺功能减退,而GSD1a患者和对照者中均无此情况(χ2 = 7.47,P < 0.005;χ2 = 27.2,P < 0.0001)。
GSD1b患者甲状腺自身免疫和甲状腺功能减退的患病率增加,而GSD1a患者几乎没有甲状腺异常的证据。即使在显性甲状腺功能减退患者中,基于促甲状腺素水平略有升高,可能推测下丘脑或垂体水平存在伴随损伤。